For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| SafeBreak Vascular Group | Subjects in the SafeBreak Vascular group will have as near to identical treatment as possible to the control group with the exception that a SafeBreak Vascular device will be placed in the peripheral IV line. SafeBreak Vascular: SafeBreak Vascular is a breakaway connector that screws into peripheral IV lines using luer connectors on each end. The device is designed to separate when a harmful force is placed on an IV line. Upon separation, valves on each side of the device close. On the patient side of the device, the valve closes to prevent the loss of blood and on the IV pump side of the device, the valve closes to stop the flow of medication. The valve closing on the IV pump side of the line causes the pump's occlusion alarm to sound and notify nurses that the IV needs attention. The nurse is able to throw away the separated SafeBreak Vascular, install a new SafeBreak, and restart the patient's infusion without the negative cascade of events that can occur when a peripheral IV fails. | 0 | None | 2 | 70 | 26 | 70 | View |
| Control Group | Subjects in the control group will receive the standard of care intervention for peripheral IVs at the study hospital. | 0 | None | 2 | 69 | 33 | 69 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Blood Chemistry Abnormalities | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Dislodgement | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Infiltration | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Phlebitis VIP =/>2 | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Occlusion | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Device Crack/Leak | SYSTEMATIC_ASSESSMENT | Product Issues | None | View |
| IV Site Bleeding/Fluid Leakage | SYSTEMATIC_ASSESSMENT | Surgical and medical procedures | None | View |
| Mental Status Change/Unwitnessed Fall | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| Skin Reactions | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Pains | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Cardiovascular | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| Nausea/Diarrhea | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Elevated Temperature | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Urinary Catheter Placed | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | None | View |
| Post-op Complication | SYSTEMATIC_ASSESSMENT | General disorders | None | View |